Last reviewed · How we verify
metformin+sibutramine
Metformin reduces hepatic glucose production and improves insulin sensitivity, while sibutramine suppresses appetite by inhibiting reuptake of serotonin and norepinephrine, together addressing hyperglycemia and weight management in type 2 diabetes.
Metformin reduces hepatic glucose production and improves insulin sensitivity, while sibutramine suppresses appetite by inhibiting reuptake of serotonin and norepinephrine, together addressing hyperglycemia and weight management in type 2 diabetes. Used for Type 2 diabetes mellitus with obesity.
At a glance
| Generic name | metformin+sibutramine |
|---|---|
| Also known as | Reduxin® Forte |
| Sponsor | Promomed, LLC |
| Drug class | Antidiabetic agent + appetite suppressant combination |
| Target | AMP-activated protein kinase (metformin); serotonin and norepinephrine transporters (sibutramine) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that decreases gluconeogenesis and enhances peripheral glucose uptake, improving glycemic control. Sibutramine is a sympathomimetic amine that acts as a serotonin-norepinephrine reuptake inhibitor, promoting satiety and reducing caloric intake. The combination targets both metabolic dysfunction and obesity-related complications in diabetic patients.
Approved indications
- Type 2 diabetes mellitus with obesity
Common side effects
- Gastrointestinal disturbance (metformin)
- Tachycardia (sibutramine)
- Hypertension (sibutramine)
- Insomnia
- Headache
- Dry mouth
Key clinical trials
- Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity (PHASE4)
- Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metformin+sibutramine CI brief — competitive landscape report
- metformin+sibutramine updates RSS · CI watch RSS
- Promomed, LLC portfolio CI